Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.

Raymond S TurnerMichaeline L HebronAbigail LawlerElizabeth E MundelNadia YusufJ Nathan StarrMuhammad AnjumFernando PaganYasar Torres-YaghiWangke ShiSanjana MulkiDalila FerranteSara MatarXiaoguang LiuGiuseppe EspositoFrank BerkowitzXiong JiangJaeil AhnCharbel Moussa

Published in: Annals of neurology (2020)

Nilotinib is safe and achieves pharmacologically relevant cerebrospinal fluid concentrations. Biomarkers of disease were altered in response to nilotinib treatment. These data support a larger, longer, multicenter study to determine the safety and efficacy of nilotinib in Alzheimer's disease. ANN NEUROL 2020 ANN NEUROL 2020;88:183-194.

Keyphrases

chronic myeloid leukemia
cerebrospinal fluid
cognitive decline
randomized controlled trial
electronic health record
machine learning
open label
big data
mild cognitive impairment
study protocol
data analysis